Generation Bio Co. Stock Price, News & Analysis

On October 15, 2021, Generation Bio (Nasdaq: GBIO) announced an upcoming oral presentation at the European Society of Gene and Cell Therapy Annual Virtual Congress, scheduled for October 19-22. The presentation will showcase preclinical advancements in retinal therapies using a novel lipid nanoparticle for broad cellular delivery. Matthew Stanton, Ph.D., emphasized the potential of their non-viral delivery system to address challenges faced by viral gene therapies. Attendees can access the presentation online on October 22 and a recorded version for 30 days afterward.

Generation Bio (Nasdaq: GBIO) reported its second-quarter 2021 financial results, showcasing a cash position of $425.2 million as of June 30, 2021, a notable increase from $262.3 million at the end of 2020. R&D expenses rose to $22.7 million, up from $13.5 million year-over-year. The net loss expanded to $30.8 million, or $0.55 per share, compared to a net loss of $17.7 million or $1.50 per share last year. The company is transitioning to a new manufacturing process and has signed a lease for a 104,000 square feet cGMP facility in Waltham, expected to be operational in 2023.

Generation Bio Co. (Nasdaq: GBIO) announces participation of CEO Geoff McDonough, M.D., in a panel discussion at the Wedbush PacGrow Healthcare Conference 2021 on August 10 at 9:10 a.m. ET. The event will focus on the company's innovations in genetic medicines for rare and prevalent diseases. A live webcast will be available on the company's investor website, with a replay accessible for 30 days post-event. Generation Bio's unique platform, utilizing closed-ended DNA and advanced lipid nanoparticle delivery, aims to provide durable treatments and scalable manufacturing for genetic therapies.

Generation Bio (Nasdaq: GBIO) announced a transition to rapid enzymatic synthesis (RES) for its closed-ended DNA manufacturing across all programs, enhancing quality, scale, and speed. A lease agreement was signed for a cGMP manufacturing facility in Waltham, MA, expected to be operational in 2023. The company anticipates submitting an IND application for hemophilia A by year-end 2023, with factor VIII expression data anticipated in late 2021. Despite incurring $104 million in lease costs and $45 million in facility investments, the company expects its cash runway to remain sufficient until 2024.

Generation Bio, a leader in genetic medicines, announced that CEO Geoff McDonough will present at the William Blair Biotech Focus Conference on July 15, 2021, at 9:00 a.m. ET. The event will feature a live webcast available on their investor website, with a replay accessible for 30 days. Generation Bio focuses on developing non-viral gene therapies aimed at providing durable treatments for various diseases. Their innovative platform utilizes closed-ended DNA and a specialized delivery system to target specific tissues for effective therapy.

Generation Bio Co. (Nasdaq: GBIO) announced that CEO Geoff McDonough will present at the JMP Securities Life Sciences Conference on June 16 at 11:30 a.m. ET. A live webcast of the presentation will be available on the company's investor website, with a replay available for 30 days. The company specializes in non-viral gene therapies aimed at providing durable treatments for various diseases, utilizing a unique platform that combines high-capacity DNA constructs and targeted delivery systems. Generation Bio is committed to broadening access to gene therapy worldwide.

Generation Bio Co. (Nasdaq: GBIO) has announced that its CEO, Geoff McDonough, will be presenting at the Jefferies Virtual Healthcare Conference on June 3, 2021, at 11:30 a.m. ET. The presentation will be accessible via a live webcast on the company’s investor website, with a replay available for 30 days after.

Generation Bio specializes in non-viral gene therapies aimed at providing durable treatments for various diseases. Their innovative platform employs closed-ended DNA (ceDNA) and a cell-targeted lipid nanoparticle system to enhance gene delivery and efficacy.

Generation Bio Co. (Nasdaq: GBIO) reported significant progress in its non-viral gene therapy platform during the 24th ASGCT Annual Meeting, showcasing the production of anti-SARS-CoV-2 antibodies in mice and advancements in manufacturing efficiency. The first quarter results revealed a cash position of $451.1 million and R&D expenses of $18.8 million. However, the company recorded a net loss of $25.6 million, widening from the previous year. Generation Bio aims to leverage these developments to address a range of diseases and drive future growth.

Generation Bio Co (Nasdaq: GBIO) has announced three digital presentations for the American Society of Gene & Cell Therapy (ASGCT) 2021 Virtual Annual Meeting from May 11-14. These presentations will showcase data on their innovative non-viral gene therapy platform, focusing on antibody gene therapy, hemophilia A programs, and ceDNA construct engineering. Chief Scientific Officer Matthew Stanton noted that the hemophilia A program is progressing well, with additional data expected by mid-year. Registered attendees can access the presentations beginning May 11.